Key statistics
On Friday, C4 Therapeutics Inc (CCCC:NSQ) closed at 2.70, -26.03% below its 52-week high of 3.65, set on Sep 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.78 |
|---|---|
| High | 2.97 |
| Low | 2.67 |
| Bid | 2.67 |
| Offer | 2.72 |
| Previous close | 2.78 |
| Average volume | 2.77m |
|---|---|
| Shares outstanding | 97.58m |
| Free float | 88.49m |
| P/E (TTM) | -- |
| Market cap | 263.46m USD |
| EPS (TTM) | -1.36 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 21:00 GMT.
More ▼
- C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- C4 Therapeutics to Participate in Upcoming March Conferences
- C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
- C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
- C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
More ▼
